Skip to content
Participate in our active studiesSubscribe to our Mailing List
AB Science
Masitinib and AB8939 – Two compounds with breakthrough mechanism of action
AB ScienceAB Science
  • Home
  • Company
    • Corporate Overview
    • Executive Commitee
    • Scientific Committee
    • Values
  • Science
    • Overview
    • Masitinib in neurodegenerative disorders
    • Masitinib in inflammatory diseases
    • AB8939 in oncology
    • Publications
  • Pipeline
    • Pipeline Overview
    • Masitinib
      • Multiple Sclerosis
      • Amyotrophic Lateral Sclerosis
      • Alzheimer’s Disease
      • Indolent Systemic Mastocytosis
      • Mast Cell Activation Syndrome
    • AB8939
  • News and Media
    • Press releases
    • In the Media
    • Webcasts
  • Investors
    • Why invest in AB Science
    • Investor Kit
    • Regulated information
      • Annual reports
      • Half-year reports
      • Social and environmental responsabilities
      • Shareholders General Meeting
      • Outstanding shares and voting rights
      • Regulated agreements
      • Board of Directors Charter
      • Information document
    • Stock Information
      • General Information
      • Analyst Coverage
    • Financial Calendar
    • Events
  • Masivet®
    • About Masivet®
    • Medical information and Pharmacovigilance
  • Careers
  • Contact
  • French
  • English
Search:
  • Home
  • Company
    • Corporate Overview
    • Executive Commitee
    • Scientific Committee
    • Values
  • Science
    • Overview
    • Masitinib in neurodegenerative disorders
    • Masitinib in inflammatory diseases
    • AB8939 in oncology
    • Publications
  • Pipeline
    • Pipeline Overview
    • Masitinib
      • Multiple Sclerosis
      • Amyotrophic Lateral Sclerosis
      • Alzheimer’s Disease
      • Indolent Systemic Mastocytosis
      • Mast Cell Activation Syndrome
    • AB8939
  • News and Media
    • Press releases
    • In the Media
    • Webcasts
  • Investors
    • Why invest in AB Science
    • Investor Kit
    • Regulated information
      • Annual reports
      • Half-year reports
      • Social and environmental responsabilities
      • Shareholders General Meeting
      • Outstanding shares and voting rights
      • Regulated agreements
      • Board of Directors Charter
      • Information document
    • Stock Information
      • General Information
      • Analyst Coverage
    • Financial Calendar
    • Events
  • Masivet®
    • About Masivet®
    • Medical information and Pharmacovigilance
  • Careers
  • Contact

Author Archives: Alexis BERNARD

You are here:
  1. Home
  2. Article author Alexis BERNARD

Presentation of the results from AB8939 preclinical program in AML in EHA 2020 Annual Congress

2020By Alexis BERNARD10 June 2020

10/06/2020 – AB Science will present results from AB8939 preclinical program in acute myeloid leukemia at the EHA 2020 Annual Congress

Postponement of AB Science Annual General Shareholders’ meeting

2020By Alexis BERNARD22 May 2020

22/05/2020 – AB Science announces the postponement of its annual general shareholders’ meeting

Live webcast on masitinib in combination with isoquercetine for the treatment of COVID-19 on Monday May 11, 2020

2020By Alexis BERNARD7 May 2020

07/05/2020 – AB Science will host a live webcast on masitinib in combination with isoquercetin for the treatment of COVID-19 on Monday May 11, 2020  

Presentation of the results from the Phase 3 AB07015 study in severe asthma at the EAACI 2020 Annual Congress

2020By Alexis BERNARD7 May 2020

07/05/2020 – AB Science will present results from its Phase 3 study in severe asthma at the EEACI 2020 Annual Congress

Authorization by ANSM to initiate Phase 2 study evaluating masitinib in combination with isoquercetin for the treatment of COVID-19

2020By Alexis BERNARD6 May 2020

06/05/2020 – AB Science granted authorization by ANSM to initiate Phase 2 study evaluating masitinib in combination with isoquercetin for the treatment of COVID-19

Annual financial results as of 31 December, 2019

2020By Alexis BERNARD30 April 2020

30/04/2020 – AB Science reports its annual financial results as of 31 December, 2019

2017

Monthly disclosure of total outstanding shares and voting rightsBy Alexis BERNARD30 April 2020

Monthly disclosure of total outstanding shares and voting rights Dated December 4, 2017 Monthly disclosure of total outstanding shares and voting rights Dated November 7, 2017 Monthly disclosure of total outstanding shares and voting rights Dated October 2, 2017 Monthly disclosure of total outstanding shares and voting rights Dated August 7, 2017 Monthly disclosure of…

2018

Monthly disclosure of total outstanding shares and voting rightsBy Alexis BERNARD30 April 2020

Monthly disclosure of total outstanding shares and voting rights Dated December 6, 2018 Monthly disclosure of total outstanding shares and voting rights Dated November 6, 2018 Monthly disclosure of total outstanding shares and voting rights Dated October 3, 2018 Monthly disclosure of total outstanding shares and voting rights Dated September 5, 2018 Monthly disclosure of…

2019

Monthly disclosure of total outstanding shares and voting rightsBy Alexis BERNARD30 April 2020

Monthly disclosure of total outstanding shares and voting rights Dated December 2, 2019 Monthly disclosure of total outstanding shares and voting rights Dated November 5, 2019 Monthly disclosure of total outstanding shares and voting rights Dated October 2, 2019 Monthly disclosure of total outstanding shares and voting rights Dated September 3, 2019 Monthly disclosure of…

2020

Monthly disclosure of total outstanding shares and voting rightsBy Alexis BERNARD30 April 2020

Monthly disclosure of total outstanding shares and voting rights Dated April 2, 2020 Monthly disclosure of total outstanding shares and voting rights Dated March 4, 2020 Monthly disclosure of total outstanding shares and voting rights Dated February 5, 2020 Monthly disclosure of total outstanding shares and voting rights Dated January 8, 2020

←1
23456789101112131415
…1617181920…
212223242526
27→
AB Science
© AB Science – All right reserved
Go to Top